UPL Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/pb6kq0cxg1rw4t7w5i5778y4.pdf

Key Takeaways


Margin & Earnings Quality

Bikash Prasad: "Only from accounting standard perspective, we had to recognize this. But overall, our net credit exposure has been reduced. We have taken this impact, an accounting non-cash impact but we feel that over the period of recovery, this entire amount will get reversed."

Balance Sheet & Deleveraging

Bikash Prasad: "we are extremely focused on further deleveraging and are actively evaluating various strategic options. At this point in time, we do not have anything material to share with you, but as and when there is something significant, we will definitely share it with you."

Regional & Platform Performance

Platform / RegionTrendCommentary
UPL SAS (India)▲ StrongRevenue up 13% (9% volume, 4% price); contribution margin up ~450 bps to 32.7%; EBITDA margin up 540 bps to 22.3%, helped by new launches.
Advanta▲ Volume, ▼ MarginRevenue up double digits on 12% volume growth; EBITDA up only 5% as higher raw seed costs, lower yield recovery from rainfall, and capacity-building overhead compressed margins.
SUPERFORM▲ GrowthRevenue up 9% led by volume; SSC segment grew 21%; contribution margin up 50 bps to 24.9%.
UPL Corp▼ Slight declineRevenue down ~3% on insecticide pricing pressure in Brazil and deliberate Q1-to-Q2 shipment phasing; fungicides and herbicides posted robust growth.
Latin America▼ DeclineRevenue down ~12%; Brazil impacted by pricing pressure on select molecules and product phasing shift.
North America▲ GrowthUp 6% driven by robust herbicide portfolio (metribuzin, clethodim, s-metolachlor) and higher mancozeb and acephate revenue.
Europe▲ GrowthUp 5% on higher herbicide and fungicide volumes; strong performance in Germany, Italy, Belgium, Spain.
Africa & Asia-Pacific▬ Flat to slightly downGrowth in Indonesia, Japan, and Africa offset by pricing headwinds in China and a few other markets; net 2% lower.
Mike Frank: "We continue to see strong agchem demand at the farm gate level, despite low commodity prices for row crops. Farmer margins are under pressure in most markets, and this is creating more demand on the post-patent side of our business."

Pricing, Phasing & the Brazil Recovery Bet

Mike Frank: "I would say there are a couple of key molecules in our portfolio where we've seen some increase in price. One example is clethodim, and another is mancozeb, where we're starting to see some prices increase out of China. This is giving us the opportunity to review our pricing globally, which we are actively doing."

Advanta: Growth with Margin Pressure


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth4% to 8% YoY growthFY26
EBITDA growth10% to 14% YoY growthFY26
Growth weightingGrowth weighted towards second half of the yearFY26
New product revenue$130 mn from new product launches, mostly in H2FY26
LATAM recoveryOptimistic for recovery in Q2, good growth in H2Q2 FY26 onwards
Pricing trajectoryVolume-led growth; blended pricing flat vs last yearQ2–Q4 FY26
COGS margin benefitBenefit from lower-cost inventory to carry throughRest of FY26
Rights issue proceedsRs. 1,688 crores ($200 mn) receivedBy end of September 2025
Effective tax rate15% to 17% range for modellingFY26
DeleveragingGearing lower than last year even after perpetual bond repaymentOver next 1–2 years
Strategic optionsAdvisors engaged; no material development yetToo early to comment

Key Metrics

MetricQ1 FY26
Revenue₹9,216 cr, ~2% higher YoY; driven by 1% increase in pricing and favorable exchange impact
Contribution margin43.4%, improvement of ~390 bps YoY
EBITDA₹1,303 cr, up 14% YoY
EBITDA margin14.1%, improved 150 bps YoY
Profit after tax (PAT)Loss of ₹176 cr, improved from loss of ₹528 cr YoY
Profit after tax and minority interest (PATMI)Loss of ₹88 cr, improvement of ~₹300 cr YoY
Net finance costs₹631 cr, down from ₹740 cr YoY
Net debt₹21,371 cr ($2,492 mn), reduction of ₹6,129 cr or $806 mn YoY
Net debt-to-EBITDA2.6x, improved from 5.4x YoY
Net working capital days86 days, reduction of 35 days YoY
UPL Corp revenue growth-3% YoY, primarily due to product phasing and insecticide pricing pressure in LATAM
UPL Corp EBITDA growth23% YoY, margin expansion of more than 135 bps
UPL SAS (India CP) revenue growth13% YoY, led by 9% volume growth and 4% improved pricing
Advanta (Seeds) revenue growthDouble-digit YoY, fueled by 12% volume expansion
SUPERFORM revenue growth9% YoY, led by volume; SSC segment grew 21% YoY
FY26 guidance: revenue growth4% to 8% vs FY25
FY26 guidance: EBITDA growth10% to 14% vs FY25